THE EFFECTIVENESS AND SAFETY OF BEDAQUILINE-CONTAINING REGIMENS IN THE TREATMENT OF PATIENTS WITH MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB): A SYSTEMATIC LITERATURE REVIEW

Miptah Farid Thariqulhaq; Tri Yunis Miko Wahyono

doi:10.54209/jurnaleduhealth.v14i3.2678

Authors

Miptah Farid Thariqulhaq Universitas Indonesia
Tri Yunis Miko Wahyono Universitas Indonesia

DOI:

https://doi.org/10.54209/jurnaleduhealth.v14i3.2678

Keywords:

bedaquiline, tuberculosis, multidrug resistant, effectiveness, safety

Abstract

Objective: MDR-TB is a life-threatening infectious disease. In recent years, RR/MDR TB sufferers have increased by 10% from 186,883 patients in 2018 to 206,030 in 2019. The success rate of treatment for RR/MDR-TB patients only reaches 57% globally. WHO has recommended bedaquiline for treatment of MDR-TB as the first drug in an all-oral regimen designed to maximize treatment outcomes. Purpose: to describe the efficacy and safety of a bedaquiline-containing regimen for the treatment of MDR-TB. Methods: Pubmed, Science Direct, and Embase online databases were used to obtain data published in the last five years where literature searches were carried out independently by researchers. The keywords used in this search are combined with the Boolean operator "AND", namely (bedaquiline) AND (multidrug resistant) AND (effectiveness). Results: Eight studies met the inclusion criteria, demonstrating a higher conversion rate of sputum cultures on the bedaquiline containing regimen between 74%-95.8% with a mean time to culture conversion between 39 days-3 months. The majority of studies reported an adverse effect of QT prolongation in patients treated with bedaquiline. Conclusion: This systematic review showed that bedaquiline is effective and safe for use in the treatment of MDR-TB. However, serious side effects of QT prolongation occurred in some respondents who were treated with bedaquiline, so an effective and efficient monitoring and surveillance system is needed to ensure best practice in the treatment of MDR-TB.

References

M. J. Culyba, C. Y. Mo, and R. M. Kohli, “Targets for combating the evolution of acquired antibiotic resistance,” Biochemistry, vol. 54, no. 23, pp. 3573–3582, 2015.

C. J. H. Von Wintersdorff et al., “Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer,” Front. Microbiol., vol. 7, p. 173, 2016.

C. Lange, K. Dheda, D. Chesov, A. M. Mandalakas, Z. Udwadia, and C. R. Horsburgh, “Management of drug-resistant tuberculosis,” Lancet, vol. 394, no. 10202, pp. 953–966, 2019.

M. J. Nasiri et al., “New insights in to the intrinsic and acquired drug resistance mechanisms in mycobacteria,” Front. Microbiol., vol. 8, p. 681, 2017.

K. Andries et al., “A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis,” Science (80-. )., vol. 307, no. 5707, pp. 223–227, 2005.

E. Huitric, P. Verhasselt, K. Andries, and S. E. Hoffner, “In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor,” Antimicrob. Agents Chemother., vol. 51, no. 11, pp. 4202–4204, 2007.

K. E. Dooley et al., “QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial,” Lancet Infect. Dis., vol. 21, no. 7, pp. 975–983, 2021.

N. Ndjeka et al., “Treatment Outcomes 24 Months after Initiating Short Bedaquiline-or Injectable-Containing Rifampicin-Resistant Tuberculosis Treatment Regimens: A Retrospective Cohort Study in South Africa”.

M. Taune et al., “Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua New Guinea,” Public Heal. Action, vol. 9, no. Suppl 1, p. S73, 2019.

J. Zhang, L. Han, L. Shields, J. Tian, and J. Wang, “A PRISMA assessment of the reporting quality of systematic reviews of nursing published in the Cochrane Library and paper-based journals,” Medicine (Baltimore)., vol. 98, no. 49, 2019.

H. Pai et al., “Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis,” BMC Infect. Dis., vol. 22, no. 1, p. 870, 2022.

Y. Zhao et al., “Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug-resistant tuberculosis: a retrospective cohort study,” Clin. Infect. Dis., vol. 68, no. 9, pp. 1522–1529, 2019.

T. S. Shim et al., “A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea,” BMC Infect. Dis., vol. 23, no. 1, p. 15, 2023.

S.-J. Zhang et al., “Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China,” BMC Infect. Dis., vol. 22, no. 1, pp. 1–12, 2022.

L. Fu et al., “Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis,” Int. J. Infect. Dis., vol. 111, pp. 138–147, 2021.

F. Wagnew, K. A. Alene, M. Kelly, and D. Gray, “The effect of undernutrition on sputum culture conversion and treatment outcomes among people with multidrug-resistant tuberculosis: a systematic review and meta-analysis,” Int. J. Infect. Dis., 2022.